Rapid Novor is Canada's largest privately-owned mass spectrometry proteomics facility with a keen focus on empowering advancements in human health with our unique de novo protein sequencing and bioinformatics technology.
EasyM™ is Rapid Novor's first proprietary clinical application of our established mass spectrometry-based protein sequencing technology for the non-invasive and precise monitoring of M-protein in patients with Multiple Myeloma during their deepest response to therapy.